Skip to main content
Top
Published in: Breast Cancer 5/2016

01-09-2016 | Original Article

Clinicopathological features of breast angiosarcoma

Authors: Kyohei Masai, Takayuki Kinoshita, Kenjiro Jimbo, Sota Asaga, Takashi Hojo

Published in: Breast Cancer | Issue 5/2016

Login to get access

Abstract

Background

Breast angiosarcomas are rare neoplasm. Due to its rarity, our therapeutic strategy is extremely limited. Therefore, we investigated the clinicopathologic features and examined the treatment for angiosarcoma compared with some literatures.

Methods

We conducted a retrospective chart and slide review of all patients in our division seen from 1997 to 2012 with a diagnosis of primary or secondary breast angiosarcoma at the National Cancer Center Hospital (Tokyo, Japan).

Results

Nine patients were diagnosed with breast angiosarcoma (six primary and three secondary cases). The median age of patients with primary angiosarcoma was 39 years (range 27–65 years). The median tumor size was 6.78 cm (range 3.0–8.8 cm). In the primary tumor, 4 patients had total mastectomy and 2 had a breast conserving surgery. 3- and 5-year disease-free survival (DFS) of the patients with primary angiosarcoma was 20 and 0 %. 5-year surviving rate of primary angiosarcoma was 50 %. In all patients with secondary angiosarcoma, recurrence was observed in all cases. But one case obtained long-term survival in local control therapy.

Conclusions

Our study demonstrates breast angiosarcoma exhibits high recurrence rates. Tumor size and surgical margin may be important factor to obtain long-term survival. In this point of view, total mastectomy with adequate tumor margin with early detection is desired. In case of recurrence, if it is local, surgery may be potentially curative.
Literature
1.
go back to reference Hodgson NC, Bowen-Wells C, Moffa E. Angiosarcomas of the breast: a review of 70 cases. Am J Clin Oncol. 2007;30:570–3.CrossRefPubMed Hodgson NC, Bowen-Wells C, Moffa E. Angiosarcomas of the breast: a review of 70 cases. Am J Clin Oncol. 2007;30:570–3.CrossRefPubMed
3.
go back to reference West JG, Qureshi A, West JE, Chacon M, Sutherland L, Haghighi B, et al. Risk of angiosarcoma following breast conservation: a clinical alert. Breast J. 2005;11:115–23.CrossRefPubMed West JG, Qureshi A, West JE, Chacon M, Sutherland L, Haghighi B, et al. Risk of angiosarcoma following breast conservation: a clinical alert. Breast J. 2005;11:115–23.CrossRefPubMed
4.
go back to reference Fletcher CDM, Unni KK, Mertens F. World Health Organization Classification of tumours: pathology and genetics of tumours of soft tissue and bone. Lyon: IARC Press; 2002. Fletcher CDM, Unni KK, Mertens F. World Health Organization Classification of tumours: pathology and genetics of tumours of soft tissue and bone. Lyon: IARC Press; 2002.
5.
go back to reference Donnell RM, Rosen PP, Lieberman PH. Angiosarcoma and other vascular tumors of the breast. Am J Surg Pathol. 1981;5:629–42.CrossRefPubMed Donnell RM, Rosen PP, Lieberman PH. Angiosarcoma and other vascular tumors of the breast. Am J Surg Pathol. 1981;5:629–42.CrossRefPubMed
7.
go back to reference Vorburger SA, Xing Y, Hunt KK, Lakin GE, Benjamin RS, Feig BW, Trent J 3rd, Burgess M, Patel S, Pollock RE, Cormier JN, et al. Angiosarcoma of the breast. Cancer. 2005;104(12):2682–8.CrossRefPubMed Vorburger SA, Xing Y, Hunt KK, Lakin GE, Benjamin RS, Feig BW, Trent J 3rd, Burgess M, Patel S, Pollock RE, Cormier JN, et al. Angiosarcoma of the breast. Cancer. 2005;104(12):2682–8.CrossRefPubMed
8.
go back to reference Adem C, Reynolds C, Ingle JN, Nascimento AG. Primary breast sarcoma: clinicopathologic series from the Mayo Clinic and review of the literature. Br J Cancer. 2004;91(2):237–41.PubMedPubMedCentral Adem C, Reynolds C, Ingle JN, Nascimento AG. Primary breast sarcoma: clinicopathologic series from the Mayo Clinic and review of the literature. Br J Cancer. 2004;91(2):237–41.PubMedPubMedCentral
9.
go back to reference Zelek L, Llombart-Cussac A, Terrier P, Pivot X, Guinebretiere JM, Le Pechoux C, et al. Prognostic factors in primary breast sarcomas: a series of patients with long-term follow-up. J Clin Oncol. 2003;21(13):2583–8.CrossRefPubMed Zelek L, Llombart-Cussac A, Terrier P, Pivot X, Guinebretiere JM, Le Pechoux C, et al. Prognostic factors in primary breast sarcomas: a series of patients with long-term follow-up. J Clin Oncol. 2003;21(13):2583–8.CrossRefPubMed
10.
go back to reference Pandey M, Mathew A, Abraham EK, Rajan B. Primary sarcoma of the breast. J Surg Oncol. 2004;87(3):121–5.CrossRefPubMed Pandey M, Mathew A, Abraham EK, Rajan B. Primary sarcoma of the breast. J Surg Oncol. 2004;87(3):121–5.CrossRefPubMed
11.
go back to reference Shabahang M, Franceschi D, Sundaram M, Castillo MH, Moffat FL, Frank DS, Livingstone AS, et al. Surgical management of primary breast sarcoma. Am Surg. 2002;68(8):673–7.PubMed Shabahang M, Franceschi D, Sundaram M, Castillo MH, Moffat FL, Frank DS, Livingstone AS, et al. Surgical management of primary breast sarcoma. Am Surg. 2002;68(8):673–7.PubMed
12.
go back to reference Monroe AT, Feigenberg SJ, Mendenhall NP. Angiosarcoma after breast-conserving therapy. Cancer. 2003;97(8):1832–40.CrossRefPubMed Monroe AT, Feigenberg SJ, Mendenhall NP. Angiosarcoma after breast-conserving therapy. Cancer. 2003;97(8):1832–40.CrossRefPubMed
13.
go back to reference Lahat G, Dhuka AR, Lahat S, Smith KD, Pollock RE, Hunt KK, et al. Outcome of locally recurrent and metastatic angiosarcoma. Ann Surg Oncol. 2009;16(9):2502–9.CrossRefPubMed Lahat G, Dhuka AR, Lahat S, Smith KD, Pollock RE, Hunt KK, et al. Outcome of locally recurrent and metastatic angiosarcoma. Ann Surg Oncol. 2009;16(9):2502–9.CrossRefPubMed
14.
go back to reference Barrow BJ, Janjan NA, Gutman H, Benjamin RS, Allen P, Romsdahl MM, et al. Role of radiotherapy in sarcoma of the breast-a retrospective review of the M.D. Anderson experience. Radiother Oncol. 1999;52(2):173–8.CrossRefPubMed Barrow BJ, Janjan NA, Gutman H, Benjamin RS, Allen P, Romsdahl MM, et al. Role of radiotherapy in sarcoma of the breast-a retrospective review of the M.D. Anderson experience. Radiother Oncol. 1999;52(2):173–8.CrossRefPubMed
15.
go back to reference Fields RC, Aft RL, Gillanders WE, Eberlein TJ, Margenthaler JA. Treatment and outcomes of patients with primary breast sarcoma. Am J Surg. 2008;196(4):559–61.CrossRefPubMed Fields RC, Aft RL, Gillanders WE, Eberlein TJ, Margenthaler JA. Treatment and outcomes of patients with primary breast sarcoma. Am J Surg. 2008;196(4):559–61.CrossRefPubMed
16.
go back to reference Guadagnolo BA, Zagars GK, Araujo D, Ravi V, Shellenberger TD, Sturgis EM. Outcomes after definitive treatment for cutaneous angiosarcoma of the face and scalp. Head Neck. 2011;33(5):661–7 (Epub 2010 Oct 19).CrossRefPubMed Guadagnolo BA, Zagars GK, Araujo D, Ravi V, Shellenberger TD, Sturgis EM. Outcomes after definitive treatment for cutaneous angiosarcoma of the face and scalp. Head Neck. 2011;33(5):661–7 (Epub 2010 Oct 19).CrossRefPubMed
17.
go back to reference Kaklamanos IG, Birbas K, Syrigos KN, Vlachodimitropoulos D, Goutas N, Bonatsos G. Breast angiosarcoma that is not related to radiation exposure: a comprehensive review of the literature. Surg Today. 2011;41(2):163–8.CrossRefPubMed Kaklamanos IG, Birbas K, Syrigos KN, Vlachodimitropoulos D, Goutas N, Bonatsos G. Breast angiosarcoma that is not related to radiation exposure: a comprehensive review of the literature. Surg Today. 2011;41(2):163–8.CrossRefPubMed
19.
go back to reference Ockenfels H, Brockmeyer N, Hengge U. Cutaneous angiosarcoma: a novel therapy with liposomal doxorubicine? J Eur Acad Dermatol Venereol. 1996;6:71–5.CrossRef Ockenfels H, Brockmeyer N, Hengge U. Cutaneous angiosarcoma: a novel therapy with liposomal doxorubicine? J Eur Acad Dermatol Venereol. 1996;6:71–5.CrossRef
20.
go back to reference Borden EC, Amato DA, Rosenbaum C, Enterline HT, Shiraki MJ, Creech RH, et al. Randomized comparison of three adriamycin regimens for metastatic soft tissue sarcomas. J Clin Oncol. 1987;5(6):840–50.PubMed Borden EC, Amato DA, Rosenbaum C, Enterline HT, Shiraki MJ, Creech RH, et al. Randomized comparison of three adriamycin regimens for metastatic soft tissue sarcomas. J Clin Oncol. 1987;5(6):840–50.PubMed
21.
go back to reference Edmonson JH, Ryan LM, Blum RH, Brooks JS, Shiraki M, Frytak S, et al. Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas. J Clin Oncol. 1993;11(7):1269–75.PubMed Edmonson JH, Ryan LM, Blum RH, Brooks JS, Shiraki M, Frytak S, et al. Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas. J Clin Oncol. 1993;11(7):1269–75.PubMed
22.
go back to reference Penel N, Bui BN, Bay JO, Cupissol D, Ray-Coquard I, Piperno-Neumann S, et al. Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX Study. J Clin Oncol. 2008;26(32):5269–74.CrossRefPubMed Penel N, Bui BN, Bay JO, Cupissol D, Ray-Coquard I, Piperno-Neumann S, et al. Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX Study. J Clin Oncol. 2008;26(32):5269–74.CrossRefPubMed
23.
go back to reference Bousquet G, Confavreux C, Magne N, de Lara CT, Poortmans P, Senkus E, et al. Outcome and prognostic factors in breast sarcoma: a multicenter study from the rare cancer network. Radiother Oncol. 2007;85:355–61.CrossRefPubMed Bousquet G, Confavreux C, Magne N, de Lara CT, Poortmans P, Senkus E, et al. Outcome and prognostic factors in breast sarcoma: a multicenter study from the rare cancer network. Radiother Oncol. 2007;85:355–61.CrossRefPubMed
24.
go back to reference Luini A, Gatti G, Diaz J, Botteri E, Oliveira E, Cecilio Sahium de Almeida R, et al. Angiosarcoma of the breast: the experience of the European Institute of Oncology and a review of the literature. Breast Cancer Res Treat. 2007;105:81–5.CrossRefPubMed Luini A, Gatti G, Diaz J, Botteri E, Oliveira E, Cecilio Sahium de Almeida R, et al. Angiosarcoma of the breast: the experience of the European Institute of Oncology and a review of the literature. Breast Cancer Res Treat. 2007;105:81–5.CrossRefPubMed
25.
go back to reference Nascimento AF, Raut CC, Fletcher CDM. Primary angiosarcoma of the breast. Clinicopathologic analysis of 49 cases suggesting that grade in not prognostic. Am J Surg Pathol. 2008;32:1896–904.CrossRefPubMed Nascimento AF, Raut CC, Fletcher CDM. Primary angiosarcoma of the breast. Clinicopathologic analysis of 49 cases suggesting that grade in not prognostic. Am J Surg Pathol. 2008;32:1896–904.CrossRefPubMed
26.
go back to reference Scow JS, Reynolds CA, Degnim AC, Petersen IA, Jakub JW, Boughey JC. Primary and secondary angiosarcoma of the breast: the Mayo Clinic experience. J Surg Oncol. 2010;101(5):401–7.PubMed Scow JS, Reynolds CA, Degnim AC, Petersen IA, Jakub JW, Boughey JC. Primary and secondary angiosarcoma of the breast: the Mayo Clinic experience. J Surg Oncol. 2010;101(5):401–7.PubMed
27.
go back to reference Fraga-Guedes C, Gobbi H, Mastropasqua MG, Botteri E, Luini A, Viale G. Primary and secondary angiosarcomas of the breast: a single institution experience. Breast Cancer Res Treat. 2012;132(3):1081–8.CrossRefPubMed Fraga-Guedes C, Gobbi H, Mastropasqua MG, Botteri E, Luini A, Viale G. Primary and secondary angiosarcomas of the breast: a single institution experience. Breast Cancer Res Treat. 2012;132(3):1081–8.CrossRefPubMed
Metadata
Title
Clinicopathological features of breast angiosarcoma
Authors
Kyohei Masai
Takayuki Kinoshita
Kenjiro Jimbo
Sota Asaga
Takashi Hojo
Publication date
01-09-2016
Publisher
Springer Japan
Published in
Breast Cancer / Issue 5/2016
Print ISSN: 1340-6868
Electronic ISSN: 1880-4233
DOI
https://doi.org/10.1007/s12282-015-0630-y

Other articles of this Issue 5/2016

Breast Cancer 5/2016 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine